Amgen stock has delivered a strong 73.5% return over the last three years, and the current checks suggest a mixed picture on ...

Near-term headwinds could sink the stock, but there is more to the story.

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

Pfizer and Amgen both grew revenue last quarter at nearly the same pace, but the engines driving that growth point toward two ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company said it has reached ...

Tests found that the foreign matter does not pose a clinical risk to patients.

Amgen (AMGN) closed at $366.44 in the latest trading session, marking a -2.06% move from the prior day. The stock's change ...

By Jonathan Stempel July 1 (Reuters) - A federal judge on Wednesday blocked Colorado from capping the price of Amgen's ...

Europe's drug regulator on Friday recommended revoking the marketing authorization for Amgen's rare autoimmune disease medicine, citing concerns over the ...

Amgen recalls 934K bottles of Corlanor and Sensipar due to foreign material and manufacturing deviations, per FDA June 23 report.

By Puyaan Singh June 29 (Reuters) - The New England Journal of Medicine on Monday retracted an article on a pivotal clinical trial that supported approval of Amgen’s rare-disease drug, citing concerns ...

Amgen has reacted with consternation to the news that treatment with its KRAS inhibitor Lumykras will no longer be funded in ...